Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
印度艾滋病毒感染者癌症患病率、危险因素和结果的研究
基本信息
- 批准号:8539193
- 负责人:
- 金额:$ 16.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-01 至 2015-07-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS Malignancy ConsortiumAcquired Immunodeficiency SyndromeAffectAwarenessBlood specimenBreastCD4 Lymphocyte CountCancer CenterCancer HospitalCancer PatientCancer Prevention TrialCervicalClinicClinicalClinical TreatmentClinical TrialsCollaborationsComorbidityCross-Sectional StudiesDataDatabasesDevelopmentEarly DiagnosisEducational process of instructingEnrollmentEnvironmental ExposureEpidemiologyFrequenciesFundingFutureGoalsGrantHIVHIV InfectionsHIV riskHealthHospital ReferralsIncidenceIndiaIndividualInfectionInstitutesInstitutionInvestigationLaboratoriesMalignant NeoplasmsMedicalMonitorMorbidity - disease rateOncogenic VirusesOutcomePatientsPeripheral Blood Mononuclear CellPersonsPlasmaPopulationPrevalencePrevention strategyPreventive InterventionProstateRegional CancerRegistriesResearchResearch PersonnelResourcesRiskRisk FactorsScienceScreening for cancerServicesSourceSpecimenStagingSurveysTherapeuticTherapeutic InterventionTissue BankingTissue BanksTreatment outcomeViralViral EpidemiologyViral Load resultbasecancer riskcancer therapycancer typecohortdemographicsfollow-upimprovedmortalityneoplasm registryprofessorprospectivepublic health relevancerepositoryresidencesample collectiontumortumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Globally, India has one of the largest populations of HIV-infected people, estimated at 2.40 million individuals. Malignancy is a known co-morbidity of HIV infection and is growing in proportion in many parts of the world. The incidence and manifestations of cancer in HIV-infected individuals in India has not yet been well characterized, and the proportion of patients with undiagnosed HIV infection who may be presenting with cancer as their first manifestation of HIV infection is not known. The goal of this proposal is to obtain information on the prevalence of HIV in the cancer population seen over a 1-2 year period at a major cancer treatment and referral center in Northern India. We will similarly assess the HIV prevalence of patients presenting to cancer screening clinics at the same institution (e.g. breast, cervical and prostate). Another goal is to collect information; demographics, HIV and clinical status at presentation, HIV and cancer risk factors, as well as information on incidence of cancer, cancer types, stage, treatments and treatment outcomes in patients with HIV and cancer. In addition we will similarly assess various cancer risk factors and the prevalence of various oncogenic viruses in patients with incident cancers (compared to concurrent control HIV+ individuals from the same HIV clinic at the same institution that do not develop cancer in the timeframe of this study. This will allow assessment of HIV prevalence in various cancers types as well as provide information on the short- term cancer incident and various risk factors and co-factors for cancer development among HIV-infected persons. Identified cancer and HIV individuals from this study will be enrolled in a cancer and HIV registry
and specimen/tissue bank, which we will help establish, for prospective follow-up and specimen collection to obtain data on cancer and HIV treatments and clinical outcomes and to provide a cohort for future research studies, including epidemiologic, laboratory and possible clinical trial. Establishment of the HIV and cancer registry with collected tumor and blood specimens will provide our Indian investigator colleagues with a valuable resource for further research (with additional future Indian outside funding). This study will involve a collaboration between investigators at UCLA, the All India Institute for Medical Sciences (AIIMS) in New Delhi and the Dr. B.R. Ambedkar Institute and Rotary Cancer Hospital (DR BRAIRCH) at AIIMS The overall goal is to better characterize the important association of HIV and cancer in India and to identify
risk factors and potential viral co-factors which may ultimately service as the basis for future therapeutic and prevention interventions for this important co-morbidity in HIV.
描述(由申请人提供):在全球范围内,印度是艾滋病毒感染者人数最多的国家之一,估计有 240 万人。恶性肿瘤是艾滋病毒感染的一种已知并发症,并且在世界许多地区其比例正在增加。印度艾滋病毒感染者癌症的发病率和表现尚未得到很好的描述,并且未确诊的艾滋病毒感染患者中可能以癌症作为艾滋病毒感染首发表现的患者比例尚不清楚。该提案的目标是获取印度北部主要癌症治疗和转诊中心 1-2 年内癌症人群中艾滋病毒流行情况的信息。我们将类似地评估同一机构癌症筛查诊所(例如乳腺癌、宫颈癌和前列腺癌)患者的艾滋病毒患病率。另一个目标是收集信息;人口统计数据、艾滋病毒和就诊时的临床状况、艾滋病毒和癌症危险因素,以及艾滋病毒和癌症患者的癌症发病率、癌症类型、阶段、治疗和治疗结果的信息。此外,我们将类似地评估各种癌症风险因素和各种致癌病毒在癌症患者中的患病率(与来自同一机构的同一艾滋病毒诊所的同时对照艾滋病毒+个体相比,这些个体在本研究的时间范围内没有患上癌症)。这将有助于评估各种癌症类型中的艾滋病毒患病率,并提供有关短期癌症事件以及艾滋病毒感染者中癌症发展的各种危险因素和辅助因素的信息。登记参加癌症和艾滋病毒登记处
我们将帮助建立样本/组织库,用于前瞻性随访和样本收集,以获得有关癌症和艾滋病毒治疗和临床结果的数据,并为未来的研究提供队列,包括流行病学、实验室和可能的临床试验。利用收集的肿瘤和血液样本建立艾滋病毒和癌症登记处将为我们的印度研究同事提供进一步研究的宝贵资源(未来还有额外的印度外部资助)。这项研究将由加州大学洛杉矶分校、新德里全印度医学科学研究所 (AIIMS) 和 B.R. 博士的研究人员合作进行。 AIIMS 的安贝德卡研究所和扶轮癌症医院 (DR BRAIRCH) 总体目标是更好地描述印度艾滋病毒与癌症之间的重要关联,并确定
风险因素和潜在的病毒辅助因素最终可能成为未来针对艾滋病毒这一重要共病的治疗和预防干预措施的基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RONALD T. MITSUYASU其他文献
RONALD T. MITSUYASU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RONALD T. MITSUYASU', 18)}}的其他基金
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
印度艾滋病毒感染者癌症患病率、危险因素和结果的研究
- 批准号:
8710116 - 财政年份:2013
- 资助金额:
$ 16.51万 - 项目类别:
South American Prevention of HIV Research Training Program (SAPHIR)
南美艾滋病毒预防研究培训计划 (SAPHIR)
- 批准号:
8474842 - 财政年份:2011
- 资助金额:
$ 16.51万 - 项目类别:
South American Prevention of HIV Research Training Program (SAPHIR)
南美艾滋病毒预防研究培训计划 (SAPHIR)
- 批准号:
8209934 - 财政年份:2011
- 资助金额:
$ 16.51万 - 项目类别:
South American Prevention of HIV Research Training Program (SAPHIR)
南美艾滋病毒预防研究培训计划 (SAPHIR)
- 批准号:
8309930 - 财政年份:2011
- 资助金额:
$ 16.51万 - 项目类别:
AMC Group Chairman, University of California, LA
AMC 集团董事长,加州大学洛杉矶分校
- 批准号:
8099873 - 财政年份:2010
- 资助金额:
$ 16.51万 - 项目类别:
UCLA-USC Combined Los Angeles Core Site
加州大学洛杉矶分校 (UCLA)-南加州大学 (USC) 联合洛杉矶核心站点
- 批准号:
8099881 - 财政年份:2010
- 资助金额:
$ 16.51万 - 项目类别:
A SINGLE ARM, OPEN-LABEL PILOT TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A QUADR
Quadr 安全性和免疫原性的单臂、开放标签试点试验
- 批准号:
7951594 - 财政年份:2009
- 资助金额:
$ 16.51万 - 项目类别:
PHASE IIA TRIAL OF 1% TOPICAL CIDOFOVIR FOR TREATMENT OF HIGH-GRADE PERIANAL SQU
阶段%20IIA%20试验%20OF%201%%20局部%20西多福韦%20FOR%20治疗%20OF%20高等级%20肛周%20SQU
- 批准号:
8167120 - 财政年份:2009
- 资助金额:
$ 16.51万 - 项目类别:
A PHASE II TRIAL OF COMBINED MODALITY THERAPY PLUS CETUXIMAB IN HIV-ASSOCIATED A
联合疗法加西妥昔单抗治疗 HIV 相关 A 患者的 II 期试验
- 批准号:
8167098 - 财政年份:2009
- 资助金额:
$ 16.51万 - 项目类别:
相似国自然基金
从CD4+、CD8+T细胞免疫活化分子及其上游调控因子表达探究健脾祛湿法治疗艾滋病免疫调节机制
- 批准号:81460716
- 批准年份:2014
- 资助金额:48.0 万元
- 项目类别:地区科学基金项目
HAART过程中HCV复制增强与肝细胞MAVS抗病毒通路的关系研究
- 批准号:81201286
- 批准年份:2012
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Heme oxygenase-1 as a tumor factor and therapeutic target for Kaposi sarcoma
血红素加氧酶-1 作为肿瘤因子和卡波西肉瘤的治疗靶点
- 批准号:
9248335 - 财政年份:2015
- 资助金额:
$ 16.51万 - 项目类别:
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
印度艾滋病毒感染者癌症患病率、危险因素和结果的研究
- 批准号:
8710116 - 财政年份:2013
- 资助金额:
$ 16.51万 - 项目类别: